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Background/aim: Nephrocalcinosis (NC) is defined as calcium deposition in the kidney parenchyma and tubules. This study aims to
determine the etiology, risk factors, and follow-up results of patients with NC in Turkey.
Materials and methods: Patients diagnosed with NC in the pediatric nephrology Department Units of 19 centers from all geographical
regions of Turkey over a 10-year period (2010–2019) were included in the study. The medical records from the centers were reviewed
and demographic data, admission complaints, medical history, systemic and genetic disorders, risk factors for NC, treatment details, and
presence of NC after one-year follow-up, were recorded retrospectively.
Results: The study sample included 195 patients (88 females, 107 males). The mean age at diagnosis was 39.44 ± 47.25 (0.5–208) months;
82/190 patients (43.2%) were diagnosed incidentally; 46/195 patients (23.6%) had an underlying disease; idiopathic hypercalciuria was
detected in 75/195 (38.4%) patients. The most common systemic diseases were distal renal tubular acidosis in 11/46 patients (23.9%),
primary hyperoxaluria in 9/46 patients (19.6%) and Bartter syndrome in 7/46 patients (15.3%). After one year of follow-up, NC resolved
in 56/159 patients (35.2%) and they all did not have an underlying systemic disease.
Conclusion: The most common presentation of NC was incidental. Distal renal tubular acidosis and primary hyperoxaluria were the
main systemic diseases leading to NC, while hypercalciuria was the most common metabolic risk factor. Nephrocalcinosis was found
to remain in most of the patients at a one-year follow-up. It may resolve particularly in patients with no underlying systemic disease.
Keywords: Bartter syndrome, hypercalciuria, nephrocalcinosis, renal tubular acidosis
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1. Introduction
Nephrocalcinosis (NC) is defined as calcium accumulation
in the kidney parenchyma and tubules [1]; it is classified
as molecular (chemical), microscopic or macroscopic and
can be seen in radiological imaging [1,2]. Molecular NC
is generally observed in patients with hypercalcemia and
resolves after the correction of hypercalcemia. Microscopic
NC may present in patients who use phosphate
preparations for bowel cleansing [3]. Nephrocalcinosis can
also be classified as medullary and cortical according to the
anatomical localization of the calcium deposition. Cortical
NC accounts for approximately 3% of NC cases, such as
renal cortical necrosis or chronic glomerulonephritis
[1–5]. Medullary NC accompanies patients with distal
renal tubular acidosis, primary hyperoxaluria, primary
hyperparathyroidism, medullary sponge kidney, and
inherited tubulopathies.
The renal prognosis of NC depends on the underlying
cause. While most patients with NC do better, diseases such
as primary hyperoxaluria type 1 could lead to end-stage
renal disease [6], so determining the underlying disease
is important for predicting the outcome and treatment
decision. The present study determines the etiologies, risk
factors, follow-up, and treatment of patients with NC in a
large number of centers in Turkey.
2. Materials and methods
Nephrocalcinosis patients of 19 Pediatric Nephrology
Department Units (Mersin University Medical Faculty,
Bakırkoy Dr Sadi Konuk Education and Research Hospital,
Kayseri City Hospital, İstanbul University Medical
Faculty, Cerrahpaşa Medical Faculty, Marmara University
Education and Research Hospital, Kartal Dr. Lütfi
Kırdar City Hospital, Mediterranean University Medical
Faculty, Gazi University Medical Faculty, Ondokuz Mayıs
University Medical Faculty, Bursa Dörtçelik Children
Hospital, İstanbul Haseki Education and Research Hospital,
Erzurum Education and Research Hospital, Erciyes
University Medical Faculty, Manisa Celal Bayar University
Medical Faculty, Anadolu Medical Center, Bahçeşehir
University School of Medicine, Konya, Dr Faruk Sukan
Obstetrics and Children Hospital, Eskişehir City Hospital)
over a 10-year period (2010–2019) were included in the
study. Mersin University Ethics Committee approved the
study (2018/245). The medical records of each center were
reviewed and demographic data, admission complaints,
medical history, systemic and genetic disorders, risk
factors for NC, treatment details, and whether NC was
still present after a one-year follow-up were recorded
retrospectively. Patients who received loop diuretics were
excluded from the study. Nephrocalcinosis diagnosis was
based on the identification of increased echogenicity on
ultrasound; hypervitaminosis D was defined if 25(OH)D
levels were above 100 ng/mL [7,8]; primary hyperoxaluria

was defined as urinary oxalate increment with confirmed
genetic analysis; secondary hyperoxaluria was defined as
hyperoxaluria secondary to chronic ingestion of excessive
amounts of oxalate precursors; distal renal tubular acidosis
(dRTA) was defined as hypokalemic hyperchloremic
metabolic acidosis, hypercalciuria, and urine pH > 5.5;
Bartter syndrome was defined as hypokalemic metabolic
alkalosis, hyperreninemia, hyperaldosteronism, and
hypercalciuria with NC; familial hypomagnesemiahypercalciuria was defined as persistent hypomagnesemia,
incomplete distal tubular acidosis, hypercalciuria, and
NC; medullary cystic disease was diagnosed in patients
with urine concentrating defects, a positive family history
for renal cysts, and the presence of medullary cysts and/
or increment medullary echogenicity in ultrasonography;
primary hyperparathyroidism was defined as chronic
increment of calcium levels and parathyroid hormone
(PTH) [9]; hypophosphatemic rickets was diagnosed in
patients with phosphaturia, hypophosphatemia, rickets
with inactivating mutations in the phosphate regulating
gene (PHEX with homologies to endopeptidases on the
X chromosome); idiopathic hypercalciuria was defined as
elevated urinary calcium excretion without concomitant
hypercalcemia and systemic disease; hypercalciuria was
defined for calcium/creatinine ratio levels in urine samples
according to age groups (0–6 months: >0.8 mg/mg, 7–12
months: >0.6 mg/mg, 1–3 years: > 0.53 mg/mg, 3–5 years:
> 0.39 mg/mg, 5–7 years: >0.28 mg/mg and >7 years:
>0.21, hyperoxaluria was defined for oxalate/creatinine
levels in spot urine samples according to age groups (0–6
months: >0.28 mg/mg, 7–24 months: >0.11 mg/mg, 2–5
years: >0.08 mg/mg, 5–14 years: >0.06 mg/mg, >16 years:
>0.03 mg/mg); hypocitraturia was defined as a citrate/
creatinine ratio in spot urine samples according to age
groups (≤5 years: <0.42 mg/mg, >5 years: <0.25 mg/mg
hyperuricosuria was defined as uric acid/creatinine levels
in spot urine samples according to age groups (< 1 year:
>2.2 mg/mg, 1–3 years: >1.9 mg/mg, 3–5 years: >1.5 mg/
mg, 5–10 years: >0.9 mg/mg and >10 years: >0.6 mg/mg;
and cystinuria was defined as cystine/creatinine levels in
spot urine samples according to age groups (< 1 month:
>0.18 mg/mg, 1–6 months: >0.11 mg/mg and > 6 months:
>0.038 mg/mg [10]. Renal failure referred to stage 3–5
chronic kidney disease.
2.1. Statistical analysis
The data analysis was conducted using SPSS v: 21.0
software. Descriptive statistics were presented as mean
± standard deviation. An independent-sample t test was
used to compare the means between age of the groups. The
dependency between categorical variables was tested using
Pearson’s chi-square test and Fisher exact chi-square test.
Numbers and percentages were used to express descriptive
statistics. A p value < 0.05 was considered statistically
significant.
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3. Results
The study was conducted with 195 patients from 19 different
centers in Turkey (88 females, 107 males). The mean age at
diagnosis was 39.44 ± 47.25 (0.5–208) months. Fourteen
patients (7.2%) were diagnosed in neonatal period.
3.1. Presentation and clinical characteristics of patients
with NC
Incidental diagnosis was made on 43.2% patients (82/190),
while 56.8% (108/190) had admission complaints such
as vomiting (n = 30, 15.8%), restlessness (n = 24, 12.6%),
abdominal pain (n = 21, 11.0%), failure to thrive (n = 12,
6.3%), fever (n = 10, 5.3%), hematuria (n = 7, 3.7%), and
dysuria (n = 4, 2.1%). Prematurity and hospitalization
history were present in 16.2% (31/191) and 28.0% (53/189)
of the patients, respectively. Consanguinity was present in
70/186 (37.6%) cases. A family history of stones was present
in 90/186 (48.4%) patients.
Vitamin D therapy was received by 43.5% (80/184) of
the patients, 69 (86.2%) were taking 400–600 IU/day and 11
(13.8%) were taking greater than 600 IU/day. The mean of
the 25(OH)2D3 levels of the patients was 29.99 ± 37.29 (7.00–
334.40) ng/mL. Vitamin D levels were lower than 30 ng/
mL, 30–100 ng/mL, >100 ng/mL in 86/135 (63.7%), 47/135
patients (34.8%), and 2/135 (1.5%) patients, respectively.
Growth retardation was present in 42/185 (22.7%), renal
failure in 7/185 (3.8%) and hypertension in 7/185 (3.8%)
patients. Growth retardation was present in 13/30 patients
with systemic diseases (43.3%); 6 had Bartter syndrome,
5 had dRTA, and 2 had Williams syndrome. In preterm
patients, growth retardation was observed in 12/31 (38.7%)
patients. All of the patients with renal failure (n = 7) had
systemic diseases; three had Bartter syndrome, three had
primary hyperoxaluria and one had dRTA. Liddle syndrome
was detected in one patient who had hypertension, while
6 patients had no detectable systemic disease leading to
hypertension.
Nephrolithiasis/urolithiasis (NL/UL) was accompanying
101/195 (51.8%) patients with NC. Eighteen (17.8%) of
those patients had systemic disease, while 83 (82.2%) had
no systemic disease.
3.2. Etiologic factors and metabolic risk factors leading to
nephrocalcinosis
Etiologic factors of patients with NC were shown in Table
1. Systemic diseases (dRTA, primary hyperoxaluria, Bartter
syndrome, familial hypomagnesemia and hypercalciuria,
medullary sponge kidney, primary hyperparathyroidism,
hypervitaminosis D, Williams syndrome, hypophosphatemic
rickets, Liddle syndrome, enamel renal syndrome, down
syndrome, glucose-galactose malabsorption, and tumor
lysis syndrome) were present in 46/195 (23.6%) patients.
Idiopathic hypercalciuria was detected in 75 (38.46%)
patients, while there was no detectable underlying reason
in remaining 74 (37.95%) patients (Table 1).
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Table 1. Etiologic factors of patients with NC.
Diseases

n= 195 %

Idiopathic hypercalciuria

75

38.46

Distal renal tubular acidosis

11

5.64

Primary hyperoxaluria

9

4.61

Bartter syndrome

7

3.59

Familial hypomagnesemia and hypercalciuria

3

1.54

Medullary sponge kidney

3

1.54

Primary hyperparathyroidism

2

1.03

Hypervitaminosis D

2

1.03

Williams syndrome

2

1.03

Hypophosphatemic rickets

2

1.03

Liddle syndrome

1

0.51

Enamel renal syndrome

1

0.51

Down syndrome

1

0.51

Glucose-galactose malabsorption

1

0.51

Tumor lysis syndrome

1

0.51

Unknown etiology

74

37.95

Hypercalciuria was the most common metabolic
risk factor accompanying NC, being detected in 95/195
(48.7%) patients, while the other metabolic risk factors
were hypocitraturia and hyperoxaluria in 48/163 (29.4%)
and 29/164 (17.7%) patients, respectively (Table 2).
Hypercalciuria ratio in patients who received vitamin
D therapy without systemic disease was 40/83 (48.2%).
Hypercalciuria with hypercalcemia was detected in 20/164
(12.2%) patients. Three of the patients with hypocitraturia
had dRTA, and three had Bartter syndrome. Remaining
42 had idiopathic hypocitraturia. Nine of the patients
with hyperoxaluria had primary hyperoxaluria, while
the remaining 20 patients were found to have secondary
hyperoxaluria.
3.3. Medications of the patients with NC
The medications were potassium citrate in 136/193
(70.4%) and thiazide diuretics in 28/183 (15.3%)
patients. Furthermore, two patients (22.2%) with
primary hyperoxaluria type 1 (n = 9) were on vitamin
B6 treatment and underwent a liver transplantation. No
patient with primary hyperparathyroidism underwent
parathyroidectomy. Other treatments noted were oral
potassium, sodium, indomethacin for Bartter syndrome,
and alkaline supplements for RTA.
3.4. One-year follow-up results of patients with NC
At one-year follow-up (n = 159), no NC was found in
56 (35.2%) patients and none had any systemic disease.
Nephrocalcinosis was still present in 103/159 (64.8%)
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Table 2. Metabolic risk factors for patients with NC.
Risk Factors

n

Patients*

%

Hypercalciuria

95

195

48.7

Hypocitraturia

48

163

29.4

Hyperoxaluria

29

164

17.7

*Number of patients who had data.

patients, of whom 46 (44.7%) had a systemic disease
and 57 (55.3%) had no detectable underlying disease.
Nephrocalcinosis resolved in six of eight patients (75%)
who were diagnosed in neonatal period after one-year
follow-up. Mean ages of the patients whose NC resolved
and unresolved were 38.51 ± 53.41 and 42.26 ± 42.27,
respectively. No statistically significant difference was
observed between the ages of patients whose NC resolved
and unresolved (p = 0.628). Statistically significant
difference was observed in terms of systemic disease
presence between patients whose NC resolved and
unresolved (p < 0.001) (Table 3). No statistically difference
was detected between patients who received potassium
citrate treatment and who did not in terms of NC presence
after one-year follow-up (p = 0.091) (Table 3). Also, there
was no statistically difference in terms of sex, prematurity,
consanguinity, vitamin D treatment, presence of
hypercalciuria, hypocitraturia, and hyperoxaluria between
patients whose NC resolved and unresolved (p = 0.308,
0.850, 0.433, 0.127, 0.584, 0.083, and 0.358, respectively)
(Tables 3 and 4).
4. Discussion
The prevalence and incidence rates of NC in children are
increasing [11]. In the United States, the incidence of NC
is in the range of 36–57 per 100,000 populations [12],
while there are no epidemiologic data on NC in children in
Turkey. This study provides demographic data and details
the etiology, risk factors and one year follow-up results
of NC cases from 19 centers from all of the geographic
regions, which are the largest NC series and a good sample
of Turkey.
The patients in the present study were mostly diagnosed
with NC incidentally, which is similar in literature [13].
Nephrocalcinosis is seen in 7%–41% of low birth-weight
neonates, which has been attributed to such additional risk
factors as the extended administration of loop diuretics,
tubular dysfunction, prolonged oxygen need, hypoxemia,
acidemia, hypovolemia, and nephrotoxic drugs [14]. The
ratio of prematurity in patients with NC was not high
(16.2%) in the study.
Vitamin D therapy is associated with NC and is
known to lead to hypercalcemia and hypercalciuria [7].

Hypercalciuria ratio in patients who received vitamin D
therapy without systemic disease was 48.2% in the present
study. It can be considered that vitamin D treatment may
have contributed to development of NC in approximately
half of the patients.
In a study, the etiology of NC in Tunisian children
was found to be primary hyperoxaluria type 1 (65%) and
dRTA (20%) [15]. In the largest series of 375 patients
with NC (1), the most frequent clinical diagnoses were
hyperparathyroidism, dRTA and medullary sponge kidney,
while approximately 7% of patients had no underlying
disease. In the present study, 23.6% of the patients had a
systemic disease, with dRTA, primary hyperoxaluria type 1
and Bartter syndrome being the most common. Idiopathic
hypercalciuria, which has been identified as a common
cause of NC in children, being seen in 13%–34% of patients
with NC [7,16], was detected in 38.46% patients in the
present study. Nephrocalcinosis in tumor lysis syndrome
can be caused by hyperphosphaturia. Hypercalcemia and
hypercalciuria leading to NC were detected in the patient
with Down Syndrome. No underlying disease or metabolic
risk factors causing NC could be identified in 37.95%
patients, although they may have a genetic abnormality
leading to NC. Longer follow-up results would give more
information about underlying reasons.
Growth retardation was the most frequent clinical
manifestation [15], being present in 43.3% of patients with
systemic disease and 38.7% of patients who were preterm.
Chronic metabolic acidosis in dRTA and hypercalciuria in
Bartter syndrome leads to excessive bone demineralization
causing growth retardation.
It is known that NL can occur in patients with NC who
have systemic diseases such as dRTA, Bartter syndrome, and
primary hyperoxaluria. In the present study, 18/46 (39.1%)
of patients with systemic disease was accompanying with
NL/UL. The literature has reported that NC can occur
in patients who develop calcium oxalate stones but with
no systemic disease [17]. Nephrolithiasis was found to
accompany with NC in 83/101 (82.2%) patients without
systemic disease, which is consistent with previous studies.
This can be attributed to presence of hypercalciuria, which
is an important underlying pathological process for both
NC and NL [18].
The treatment of NC is directed by the underlying
reason. For example, parathyroidectomy in the presence
of primary hyperparathyroidism; increased fluid intake,
restriction of sodium intake and thiazide diuretics if
hypercalciuria is present; and potassium citrate treatment
in those with hypocitraturia and a urine pH <7 [6].
Potassium citrate increases the solubility of calcium in
urine and can limit NC. In the present study most of the
patients were on potassium citrate treatment (70.4%). After
one-year follow-up, there was no significant difference
between patients who received potassium citrate and who
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Table 3. Comparison of demographic, clinical characteristics, and potassium citrate
treatments of the patients whose NC resolved and unresolved after one-ear follow-up
(n = 159).
Variables

Nephrocalcinosis
No

Sex
Prematurity

Yes

p

n

%

n

%

Male
Female

33
23

58.9
41.1

52
51

50.5
49.5

No

47

83.9

89

86.4

Yes

9

16.1

14

13.6

0.308
0.850

No

38

67.9

62

60.2

Consanguinity

Yes

18

32.1

41

39.8

Vitamin D treatment

No
Yes

27
29

48.2
51.8

64
39

62.1
37.9

0.127

Systemic disease

No
Yes

56
0

100.0
0.0

57
46

55.3
44.7

<0.001

No

19

33.9

21

20.4

Yes

37

66.1

82

79.6

Potassium citrate
treatment

0.433

0.091

Table 4. Comparison of metabolic risk actors of the patients whose nc resolved
and unresolved.
Variables

Nephrocalcinosis
No

Yes

p

n*

%

n*

%

Hypercalciuria

No
Yes

26
30

46.4
53.6

52
50

51.0
49.0

0.584

Hypocitraturia

No
Yes

37
10

78.7
21.3

55
33

62.5
37.5

0.083

Hyperoxaluria

No
Yes

39
6

86.7
13.3

69
19

78.4
21.6

0.358

*Number of patients who had data.

did not in terms of NC presence. So, we can conclude that
potassium citrate treatment is not effective on resolution
of NC.
Nephrocalcinosis is a consequence of hypercalciuria.
Increased urinary calcium load arises either through
increased calcium absorption (extra-renal causes) or
impaired calcium reabsorption within the renal tubule.
Macroscopic NC rarely resolves. After treatment for
hypercalciuria and following corrective intestinal surgery
in hyperoxaluria, a partial reversal of NC has been reported
[6]. On the other hand, it was demonstrated that neonatal-
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acquired NC resolves by 50% during the first year of life
and to 75% by school age without having an impact on
kidney function [19,20]. In the present study, after oneyear follow-up, neonatal-acquired NC resolved in 75%
of the patients, which is consistent with the literature.
Nephrocalcinosis did not resolve in 103/159(64.8%)
patients, of whom 46 (44.7%) had an underlying systemic
disease. An unknown genetic abnormality can present
57/103 (55.3%) patients with no systemic disease and in
whom NC was still present. Nephrocalcinosis resolved in
56/159 patients (35.2%) with no systemic diseases after a
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follow-up of one year, which led us to conclude that NC
may resolve particularly in patients with no underlying
systemic disease.
The limitation of the present study is its retrospective
design, which prevents the garnering of detailed data
from all patients. Genetic analysis for detecting CYP24A1
mutations or SLC34A1 variants was not available in
most of the centers. These mutations could have led to
NC in some of the patients with no underlying disease.
Prospective studies with a longer period follow-up may
give more information about the etiology and prognosis of
NC in Turkish children.

In conclusion, the most common presentation of NC
was incidental. Distal renal tubular acidosis, primary
hyperoxaluria, and Bartter syndrome were the main
systemic diseases leading to NC. Hypercalciuria was the
most common metabolic risk factor. Most of the patients
were found to still have NC at a one-year follow-up.
Nephrocalcinosis may resolve particularly in patients who
did not have an underlying systemic disease.
Informed consent
This study was approved by Mersin University Ethics
Committee (2018/245).
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